These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22875571)

  • 1. [Intracellular signaling transduction pathways. Potential targets in the treatment of rheumatic diseases].
    Frommer KW; Geyer M; Firestein GS
    Z Rheumatol; 2012 Aug; 71(6):460-7. PubMed ID: 22875571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intracellular therapeutic procedures].
    Müller-Ladner U; Neumann E
    Z Rheumatol; 2012 Aug; 71(6):459. PubMed ID: 22802022
    [No Abstract]   [Full Text] [Related]  

  • 3. [Conventional basis therapy of rheumatoid arthritis. Effects within and outside cells].
    Keyßer G
    Z Rheumatol; 2012 Aug; 71(6):468-72. PubMed ID: 22802023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New kinase inhibitors].
    Rubbert-Roth A
    Z Rheumatol; 2012 Aug; 71(6):479-84. PubMed ID: 22777068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the future of targeted therapy in rheumatology: biologics or small molecules?
    Mócsai A; Kovács L; Gergely P
    BMC Med; 2014 Mar; 12():43. PubMed ID: 24620738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recent progress in clinical trials for rheumatic diseases].
    Tanaka Y
    Nihon Rinsho; 2009 Mar; 67(3):619-25. PubMed ID: 19280942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel immunological targets in rheumatic diseases: clues from current therapies.
    D'Acquisto F; Rattazzi L; Piras G; Galuppo ML
    Drug Discov Today; 2014 Aug; 19(8):1155-60. PubMed ID: 24984284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review: basics of drug development in rheumatology.
    Mina-Osorio P
    Arthritis Rheumatol; 2015 Oct; 67(10):2581-90. PubMed ID: 26138901
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of biological agents and tissue engineering approaches on the treatment of rheumatic diseases.
    da Silva MA; Martins A; Teixeira AA; Reis RL; Neves NM
    Tissue Eng Part B Rev; 2010 Jun; 16(3):331-9. PubMed ID: 20025434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease.
    Moitra RK; Ledingham JM; Hull RG; McCrae FC; Thomas AL; Shaban R; Mackay KR
    Rheumatology (Oxford); 2005 Feb; 44(2):256-7. PubMed ID: 15637036
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of cardiovascular risk factors].
    Krüger K
    Z Rheumatol; 2016 Mar; 75(2):173-80; quiz 181-2. PubMed ID: 26924198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Emerging Role of Curcumin in the Modulation of TLR-4 Signaling Pathway: Focus on Neuroprotective and Anti-Rheumatic Properties.
    Panaro MA; Corrado A; Benameur T; Paolo CF; Cici D; Porro C
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic rheumatic diseases: From biological agents to small molecules.
    Sarzi-Puttini P; Ceribelli A; Marotto D; Batticciotto A; Atzeni F
    Autoimmun Rev; 2019 Jun; 18(6):583-592. PubMed ID: 30959214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination of biologics : where do we stand?].
    Härle P
    Z Rheumatol; 2013 Nov; 72(9):878-84. PubMed ID: 24193190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological treatment of rheumatic diseases].
    Procházková L; Böhmová J; Soucek M
    Vnitr Lek; 2006 Jun; 52(6):632-9. PubMed ID: 16871769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases.
    Gabay C; McInnes IB
    Arthritis Res Ther; 2009; 11(3):230. PubMed ID: 19519923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
    Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
    Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
    Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
    J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.